As a leader in the heparin industry, with the two decades of production experience and excellent production capacity, Dongcheng has a vertically integrated industrial structure to ensure the product quality and traceability; it has powerful qualification certification background: the first Chinese pharmaceutical company which passes the MFDS GMP audit by the Korea Food & Drug Administration, the first Chinese pharmaceutical company which passes the GMP on-site inspections by PMDA of Japan, the GMP certificates issued by BGV in Hamburg, Germany and NMPA in China, as well as the CEP certificate issued by EDQM in Europe; also, it participated in the revisions of the Chinese Pharmacopoeia (2010/2015), European Pharmacopoeia and United States Pharmacopeia concerning the heparin sodium API.

 

The company, as the largest global producer of chondroitin sulfate, is the first producer in China which passes the USP certification of the United States; and holds the CEP certificate issued by EDQM in the European Union, and the GMP certificates issued by BGV in Hamburg, Germany, MFDS in Korea, ANVISA in Brazil and CFDA in China. In view of its technological authority in the domestic biochemical industry, the company was invited to participate in the formulation of the product quality standard for chondroitin sulfate sodium in the Chinese Pharmacopoeia (2010/2015 edition). In 2016, the company acquired Sino Siam Biotechnique Co., Ltd., and it also holds the USP certification of the United States and the HACCP certificate issued by the Thailand Health Authority, which further consolidate its leading position in the global chondroitin industry.

 

The company has a well-established global sales network, and exports to more than 50 countries and regions in the world, with the customers covering the world’s well-known pharmaceutical producers and intermediaries. With the continuous expanding influence of its products in the international market, the company has achieved the sustained and stable growth in the business performance. Currently, the company has established the long-term stable and good cooperation with the world’s top pharmaceutical and health enterprises; and actively nutures and expands the domestic market.